Literature DB >> 3106810

Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.

G Salen, V Berginer, V Shore, I Horak, E Horak, G S Tint, S Shefer.   

Abstract

We investigated the effect of chenodeoxycholic acid on cerebrospinal fluid sterol and protein composition in six patients with cerebrotendinous xanthomatosis, a progressive neurologic disease, and in 11 control subjects. In the cerebrospinal fluid from the controls, the mean (+/- SD) levels of cholesterol and cholestanol were 400 +/- 300 and 4 +/- 7 micrograms per deciliter, respectively. The levels were almost 1.5 and 20 times higher in cerebrospinal fluid from untreated patients with cerebrotendinous xanthomatosis. Cholestanol levels were also markedly elevated in the plasma of untreated patients, but their plasma cholesterol levels (215 +/- 61 mg per deciliter) were not different from control values. Treatment with chenodeoxycholic acid reduced cerebrospinal fluid cholesterol by 34 percent and cholestanol threefold. Plasma cholestanol levels also decreased sharply. Normal cerebrospinal fluid contained small quantities of albumin, apolipoproteins, and lecithin:cholesterol acyltransferase. In cerebrospinal fluid from untreated patients with cerebrotendinous xanthomatosis, immunoreactive apolipoprotein B or apolipoprotein B fragment was increased about 100-fold and albumin about 3.5-fold; apolipoprotein AI, apolipoprotein D, and lecithin:cholesterol acyltransferase were 1.5 to 3 times more concentrated. Apolipoprotein AIV and apolipoprotein E concentrations were comparable to those in controls, and apolipoprotein AII was considerably decreased. During treatment, the concentrations of albumin and apolipoproteins AI and B declined. These results suggest that increased cerebrospinal fluid sterols are derived from plasma lipoproteins by means of a defective blood-brain barrier in patients with cerebrotendinous xanthomatosis. Therapy with chenodeoxycholic acid reestablished selective permeability of the blood-brain barrier and normalized the concentrations of sterol and apolipoprotein in the cerebrospinal fluid.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106810     DOI: 10.1056/NEJM198705143162002

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  19 in total

1.  Magnetic resonance imaging of the brain and spinal cord in cerebrotendinous xanthomatosis.

Authors:  K S Bencze; D R Vande Polder; L D Prockop
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

2.  Cerebrotendinous xanthomatosis--the spectrum of imaging findings.

Authors:  Arunachalam Pudhiavan; Alka Agrawal; Sangit Chaudhari; Anil Shukla
Journal:  J Radiol Case Rep       Date:  2013-04-01

Review 3.  Overcoming the divide between ataxias and spastic paraplegias: Shared phenotypes, genes, and pathways.

Authors:  Matthis Synofzik; Rebecca Schüle
Journal:  Mov Disord       Date:  2017-02-14       Impact factor: 10.338

Review 4.  Cerebrotendinous xanthomatosis: clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodeoxycholic acid.

Authors:  M Donaghy; R H King; R O McKeran; M S Schwartz; P K Thomas
Journal:  J Neurol       Date:  1990-06       Impact factor: 4.849

5.  'Hot cross bun' sign in a case of cerebrotendinous xanthomatosis: a rare neuroimaging observation.

Authors:  Rajendra Singh Jain; Raghavendra Bakki Sannegowda; Amit Agrawal; Deepika Hemrajani; Rahul Jain; Tarun Mathur
Journal:  BMJ Case Rep       Date:  2013-02-14

6.  Cerebrotendinous xanthomatosis: the effectiveness of high-dose piracetam for the treatment of cerebellar and sensorial ataxia.

Authors:  Ugur Uygunoglu; Aysegul Gunduz; Sukriye F Menku; Basak Yilmaz; Esra Hatipoglu; Cengiz Yalcinkaya; Sabahattin Saip; Hulya Apaydin
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

7.  A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Gian Nicola Gallus; Maria Teresa Dotti; Antonio Federico
Journal:  J Inherit Metab Dis       Date:  2014-01-18       Impact factor: 4.982

Review 8.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

9.  Cerebrotendinous xanthomatosis: a treatable hereditary neuro-metabolic disease.

Authors:  Ana Claudia Rodrigues de Cerqueira; Antônio Egídio Nardi; Jose Marcelo Ferreira Bezerra
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

10.  Levels of apolipoprotein A-II in cerebrospinal fluid in patients with neuroborreliosis are associated with lipophagocytosis.

Authors:  L Táborský; P Adam; O Sobek; M Dostál; J Dvoráková; L Dubská
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.